The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

CVS Health Corp

NYSE: CVS
Last

(U.S.) $94.21

Today's change+1.90 +2.06%
Updated December 17 3:58 PM EST. Delayed by at least 15 minutes.
 

CVS Health Corp

NYSE: CVS
Last

(U.S.) $94.21

Today's change+1.90 +2.06%
Updated December 17 3:58 PM EST. Delayed by at least 15 minutes.

CVS Health Corp Hits New 52-week High

CVS Health Corp closed up sharply Wednesday, rallying (U.S.)$1.90 or 2.06% to (U.S.)$94.21 and setting a new 52-week high. Over the last five days, shares have gained 4.55% and 31.63% year to date. Shares have outperformed the S&P 500 by 28.01% during the last year.

Key company metrics

  • Open(U.S.) $92.82
  • Previous close(U.S.) $92.31
  • High(U.S.) $94.75
  • Low(U.S.) $92.70
  • Bid / Ask(U.S.) $94.21 / (U.S.) $94.22
  • YTD % change+31.63%
  • Volume5,992,920
  • Average volume (10-day)4,762,343
  • Average volume (1-month)4,132,651
  • Average volume (3-month)4,618,479
  • 52-week range(U.S.) $64.95 to (U.S.) $94.75
  • Beta1.04
  • Trailing P/E24.32×
  • P/E 1 year forward20.53×
  • Forward PEG1.41×
  • Indicated annual dividend(U.S.) $1.10
  • Dividend yield1.17%
  • Trailing EPS(U.S.) $3.87
Updated December 17 3:58 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+3.39%

Based on its net profit margin of 3.39%, CVS Health Corp is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX2.50%Sector:Non-Cyclical Consumer Goods & ServicesIndustry:Retail - Drugs
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue35,02134,60232,68932,782
Total other revenue--------
Total revenue35,02134,60232,68932,782
Gross profit6,4686,3245,9426,331
Total cost of revenue28,55328,27826,74726,451
Total operating expense33,29632,39430,66530,573
Selling / general / administrative4,2224,1163,9184,122
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)521----0
Other operating expenses, total--------
Operating income1,7252,2082,0242,209
Interest income (expense), net non-operating-158-161-161-138
Gain (loss) on sale of assets--------
Other--------
Income before tax1,5722,0501,8662,074
Income after tax9481,2461,1291,262
Income tax, total624804737812
Net income9481,2461,1291,261
Total adjustments to net income--------
Net income before extra. items9481,2461,1291,262
Minority interest------0
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items9481,2461,1291,262
Inc. avail. to common incl. extra. items9481,2461,1291,261
Diluted net income9481,2461,1291,261
Dilution adjustment--------
Diluted weighted average shares1,1641,1741,1901,202
Diluted EPS excluding extraordinary itemsvalue per share0.811.060.951.05
Dividends per sharevalue per share0.280.280.280.23
Diluted normalized EPSvalue per share1.081.060.951.05